These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27687237)

  • 1. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Aslan A; Aras T; Özdemir E
    Leuk Lymphoma; 2017 Mar; 58(3):754-755. PubMed ID: 27687237
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
    Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Yared JA; Hardy N; Singh Z; Hajj S; Badros AZ; Kocoglu M; Yanovich S; Sausville EA; Ujjani C; Ruehle K; Goecke C; Landau M; Rapoport AP
    Bone Marrow Transplant; 2016 Jun; 51(6):850-2. PubMed ID: 26828905
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
    Issa AK; Westin JR
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):483-487. PubMed ID: 27364263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma.
    Hwang YY; Khong PL; Kwong YL
    Ann Hematol; 2017 Jul; 96(7):1219-1220. PubMed ID: 28434018
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
    Steinerová K; Jindra P; Lysák D; Karas M
    Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
    Zhao L; Yang Y; Li W; Li T; Gao Q
    Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 14. Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.
    Foran AE; Nadel HR; Lee AF; Savage KJ; Deyell RJ
    J Pediatr Hematol Oncol; 2017 Jul; 39(5):e263-e266. PubMed ID: 27841828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant.
    Alinari L; Blum KA
    Blood; 2016 Jan; 127(3):287-95. PubMed ID: 26576863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2019 Jun; 60(6):1595-1597. PubMed ID: 30732495
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Hodgkin disease relapse after allogeneic transplantation with nivolumab. Report of two cases].
    Carvallo C; Negrete F; Morales R; Lobos N; Rojas M; Jara K; Schüler C; Vidal M; Garnham N; Mosso C
    Rev Med Chil; 2021 Oct; 149(10):1507-1511. PubMed ID: 35319641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.